$KRYS

I think you're (inadvertently) making a strong bear case for $KRYS. If this is a wax-wane/acute type treatment (presumably due to cost?) then there's severe downside to this launch, since this valuation seems to be pricing in full 52 vials/year for the apparently tiny population